Let me try to explain it. This is the PD1 from BMS and it is phase III randomized to either PD1 or the doctor/patient choice of dacarbazine or taxol/carbo. 2/3 of participants will get PD1 the rest the dacarbazine or taxol/carbo. Overall survival is the endpoint they wish to discover. There is no crossover if you should progress on the dacarbazine or carbo/taxol. You must have a tumor that can be biopsied prior to the start of therapy. You can’t have active brain mets, or ocular melanoma. You also can’t have prior PD1 therapy. Although this therapy listing reads it is not recruiting, it is open according to BMS. Anything else I can answer? How are things going?
Viewing 3 posts - 1 through 3 (of 3 total)
The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.